3-Piperidinecarboxamide, N-(4-chlorophenyl)-5,5-difluoro-1-[3-(2-furanyl)benzoyl]- manufacturers
- CCG-222740
-
- $59.00 / 5mg
-
2025-11-09
- CAS:1922098-69-8
- Min. Order:
- Purity: 98.79%
- Supply Ability: 10g
|
| | 3-Piperidinecarboxamide, N-(4-chlorophenyl)-5,5-difluoro-1-[3-(2-furanyl)benzoyl]- Basic information |
| Product Name: | 3-Piperidinecarboxamide, N-(4-chlorophenyl)-5,5-difluoro-1-[3-(2-furanyl)benzoyl]- | | Synonyms: | 3-Piperidinecarboxamide, N-(4-chlorophenyl)-5,5-difluoro-1-[3-(2-furanyl)benzoyl]-;Rho-associated kinase,CCG222740,Rho-kinase,Rho,CCG-222740,CCG 222740,Inhibitor,inhibit,muscle,actin,factor,MRTF,transcription,ROK,metastasis,protein,Rho-associated protein kinase,myocardin-related,fibrosis,Ras,melanoma,orally,expression,ROCK,alpha-smooth;N-(4-Chlorophenyl)-5,5-difluoro-1-(3-(furan-2-yl)benzoyl)piperidine-3-carboxamide;CCG-222740, 10 mM in DMSO;CCG-222740 ，S6673 | | CAS: | 1922098-69-8 | | MF: | C23H19ClF2N2O3 | | MW: | 444.86 | | EINECS: | | | Product Categories: | | | Mol File: | 1922098-69-8.mol | ![3-Piperidinecarboxamide, N-(4-chlorophenyl)-5,5-difluoro-1-[3-(2-furanyl)benzoyl]- Structure](CAS/20200331/GIF/1922098-69-8.gif) |
| | 3-Piperidinecarboxamide, N-(4-chlorophenyl)-5,5-difluoro-1-[3-(2-furanyl)benzoyl]- Chemical Properties |
| Boiling point | 657.1±55.0 °C(Predicted) | | density | 1.40±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO:107.0(Max Conc. mg/mL);240.52(Max Conc. mM)
Ethanol:89.0(Max Conc. mg/mL);200.06(Max Conc. mM) | | form | Solid | | pka | 13.69±0.70(Predicted) | | color | Light yellow to yellow |
| | 3-Piperidinecarboxamide, N-(4-chlorophenyl)-5,5-difluoro-1-[3-(2-furanyl)benzoyl]- Usage And Synthesis |
| Uses | CCG-222740 is an orally active and selective Rho/myocardin-related transcription factor (MRTF) pathway inhibitor[1]. CCG-222740 is also a potent inhibitor of alpha-smooth muscle actin protein expression. CCG-222740 effectively reduces fibrosis in skin and blocks melanoma metastasis[2]. | | in vivo | CCG-222740 (oral gavage; 100 mg/kg/day for 7 days) significantly reduces α-SMA levels in the pancreas of caerulein-stimulated KC mice[1].
| Animal Model: | KC mice (LSL-KrasG12D/+; Pdx-1-Cre) of age at 9 weeks[1] | | Dosage: | 100?mg/kg | | Administration: | Oral gavage; daily; for 7 days | | Result: | Reduced α-SMA levels in the pancreas of caerulein-stimulated KC mice.
|
| | References | [1] Leal AS, et al. The Rho/MRTF pathway inhibitor CCG-222740 reduces stellate cell activation and modulates immune cell populations in KrasG12D; Pdx1-Cre (KC) mice. Sci Rep. 2019 May 8;9(1):7072. DOI:10.1038/s41598-019-43430-0
[2] Yu-Wai-Man C, et al. Local delivery of novel MRTF/SRF inhibitors prevents scar tissue formation in a preclinical model of fibrosis. Sci Rep. 2017 Mar 31;7(1):518. DOI:10.1038/s41598-017-00212-w |
| | 3-Piperidinecarboxamide, N-(4-chlorophenyl)-5,5-difluoro-1-[3-(2-furanyl)benzoyl]- Preparation Products And Raw materials |
|